Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.

Pharmaceutical

Evotec

Laszlo Reisch

Laetitia Rouxel

Craig Dowling

Cord Dohrmann

Cristina Costantin

Hans-Ulrich Wolf

Scientific Research Team

Leadership Team

Business Development and Strategy Team

Clinical and Regulatory Affairs Team

Information Technology Team

Finance and Accounting Team